Nephros Company Top Insiders
NEPH Stock | USD 1.61 0.06 3.87% |
Nephros' insiders are aggressively buying. The analysis of insiders' sentiment of trading Nephros stock suggests that almost all insiders are extremely bullish at this time. Nephros employs about 31 people. The company is managed by 11 executives with a total tenure of roughly 13 years, averaging almost 1.0 years of service per executive, having 2.82 employees per reported executive.
Daron Evans CEO CEO and President Acting CFO, Director and Member of Audit Committee |
Andrew Astor CEO CFO, CEO |
Nephros' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-05-30 | Arthur H Amron | Acquired 3000 @ 2.24 | View | ||
2024-05-28 | Arthur H Amron | Acquired 2000 @ 2.22 | View | ||
2024-05-16 | Robert R Jr. Banks | Acquired 50000 @ 2.24 | View | ||
2023-12-07 | Robert R Jr. Banks | Acquired 18000 @ 2.2 | View |
Monitoring Nephros' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Nephros |
Nephros Management Team Effectiveness
The company has return on total asset (ROA) of (0.0796) % which means that it has lost $0.0796 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1561) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Nephros' Asset Turnover is increasing as compared to previous years.The Nephros' current Common Stock Shares Outstanding is estimated to increase to about 10.9 M, while Net Loss is forecasted to increase to (6.3 M).
Nephros Workforce Comparison
Nephros is considered to be number one stock in number of employees category among its peers. The total workforce of Consumer Discretionary industry is now estimated at about 41,427. Nephros adds roughly 31.0 in number of employees claiming only tiny portion of stocks in Consumer Discretionary industry.
The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1. Nephros Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nephros insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amron Arthur H a day ago Acquisition by Amron Arthur H of 3666 shares of Nephros subject to Rule 16b-3 | ||
Spandow Oliver J. over a month ago Acquisition by Spandow Oliver J. of 7062 shares of Nephros at 6.82 subject to Rule 16b-3 | ||
Lobo Wesley S. over two months ago Acquisition by Lobo Wesley S. of 114178 shares of Nephros at 8.66 subject to Rule 16b-3 | ||
Amron Arthur H over six months ago Acquisition by Amron Arthur H of 2000 shares of Nephros at 2.2207 subject to Rule 16b-3 | ||
Harris Joseph Michael over six months ago Acquisition by Harris Joseph Michael of 7323 shares of Nephros at 2.14 subject to Rule 16b-3 | ||
Amron Arthur H over six months ago Acquisition by Amron Arthur H of 7062 shares of Nephros at 6.82 subject to Rule 16b-3 | ||
Arthur Amron over six months ago Acquisition by Arthur Amron of 3666 shares of Nephros subject to Rule 16b-3 | ||
Alisa Lask over six months ago Acquisition by Alisa Lask of 7080 shares of Nephros subject to Rule 16b-3 |
Nephros Notable Stakeholders
A Nephros stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nephros often face trade-offs trying to please all of them. Nephros' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nephros' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daron Evans | CEO and President Acting CFO, Director and Member of Audit Committee | Profile | |
Andrew Astor | CFO, CEO | Profile | |
Robert Banks | CEO President | Profile | |
Greg Lucas | President Systems | Profile | |
Alfred Vargas | Director Operations | Profile | |
Vashone Thomas | Regulatory, Quality | Profile | |
Joleen Turner | VP Devel | Profile | |
Judy CFA | Chief Officer | Profile | |
Judy Mazzini | Controller | Profile | |
MS MBA | Inc Products | Profile | |
Brianne McGuire | Marketing Brand | Profile |
About Nephros Management Performance
The success or failure of an entity such as Nephros often depends on how effective the management is. Nephros management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nephros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nephros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.15) | (0.16) | |
Return On Capital Employed | (0.16) | (0.17) | |
Return On Assets | (0.13) | (0.14) | |
Return On Equity | (0.19) | (0.20) |
Nephros Workforce Analysis
Traditionally, organizations such as Nephros use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nephros within its industry.Nephros Manpower Efficiency
Return on Nephros Manpower
Revenue Per Employee | 459.3K | |
Revenue Per Executive | 1.3M | |
Net Loss Per Employee | 50.8K | |
Net Loss Per Executive | 143.2K | |
Working Capital Per Employee | 203K | |
Working Capital Per Executive | 572K |
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |